National Atomic Co Kazatomprom JSC ADR (KAP)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 59.50 |
|---|---|
| 52-week range | 47.80 – 93.00 |
| Return, 1 month / 3 months | −13.1% / −10.5% |
| Return, 1 year / 3 years | +18.2% / +87.4% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 48.6% |
| Worst drawdown (1 year) | -32.1% |
| Average daily value traded | 4.67M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
National Atomic Company Kazatomprom is the state-owned uranium producer of Kazakhstan, based in Astana. It mines natural uranium and processes it into uranium concentrate, which it supplies to nuclear power plant operators and other customers in the nuclear fuel cycle around the world. The company also holds interests in related operations such as uranium conversion and fuel fabrication through partnerships, and it sells its output under long-term contracts as well as on the spot market.
National Atomic Co Kazatomprom JSC ADR trades under the code KAP on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
National Atomic Co Kazatomprom JSC ADR (KAP) trades on the London Exchange in UK. It last closed at USD 59.50 on 23 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 2,674 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 18.2% and over the last three months it fell 10.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -17.1% | ||
| From 52-week high | -34.8% | ||
| Momentum | 39 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.5% | ||
| 6-month return | -32.1% | ||
| 12-month return, skipping the last month | 36.1% | ||
| Stability (higher is calmer) | 37 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.1% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 4.67M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −7.6% |
|---|---|
| 1 month | −13.1% |
| 3 months | −10.5% |
| 6 months | −32.1% |
| 1 year | +18.2% |
| 3 years | +87.4% |
| 5 years | +79.9% |
Signals
| 50-day / 200-day average | 68.16 / 71.75 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 2.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Jul 2026 | KZT 2.6798 |
| 14 Jul 2025 | KZT 2.2945 |
| 30 May 2024 | KZT 2.5865 |
| 12 Jul 2023 | KZT 1.7401 |
| 12 Jul 2022 | KZT 1.8135 |
| 12 Jul 2021 | KZT 1.3562 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.